Stocks
SK Hynix Announces 40 Trillion Won Share Cancellation
SK Hynix announced a planned share cancellation of 40 trillion won and began executing purchases immediately from the day of the announcement. First-day buyback applications totaled 650,000 shares, which at the prior closing price of 1.5 million won implies roughly 975 billion won purchased in a single day—a pace that would require averaging 645.2 billion won in daily purchases over the three-month acquisition period. The volume represents 3.3% of total outstanding shares, with the acquisition period set for three months starting August 20.
The more significant change was to the 2025-2027 shareholder return policy, shifting the standard from 'up to' 50% of cumulative free cash flow to '50% or more.' Returns will combine share buyback and cancellation with cash dividends, with specifics to be disclosed at the third-quarter earnings announcement. Based on Bloomberg consensus, cumulative free cash flow for 2025-2027 is projected to reach 473 trillion won, meaning up to 236 trillion won could be allocated to shareholder returns, according to market analysis.
Meritz Securities analyst Kim Sun-woo assessed the announcement as satisfying all three of timing, scale, and expectation. The view was that it offered an effective solution to undervaluation at an unexpected moment while also signaling further follow-up measures, making it both stable and beyond expectations. SK Hynix surged more than 13% on the day, touching 1.7 million won.
On air, it was noted that SK Hynix's 50%-or-more free cash flow standard uses a different calculation method from Micron's or SanDisk's 100%-of-excess-cash standard, so it cannot simply be judged as lower by comparison—in fact, the scale was said to exceed even the shareholder return plan of Kioxia, which had posted an earnings miss. The announcement was also characterized as a qualitative shift for SK Hynix into a stock directly linked to its earnings and performance, with the scale noted as comparable to the amount raised in its ADR capital increase at the time.
It was reported that Samsung Electronics will convene a board meeting in August to resolve on a shareholder return plan exceeding 100 trillion won, including a special cash dividend. On air, the suggestion was made that Samsung Electronics needs to lean primarily toward share cancellation, with the prospect raised that a share cancellation could also reopen discussion of the previously shelved stock split issue. Reuters also reported that Samsung Electronics raised foundry order prices by 10-15% for both 4nm and 5nm/8nm processes starting in July, and the stock surged about 9% on the day to recover to 270,000 won.
Moderna, Merck Surge on mRNA Cancer Vaccine Trial Success
Moderna's personalized mRNA melanoma cancer vaccine, intismeran, confirmed meaningful results in delaying recurrence and metastasis in Phase 3 combination trials with Merck's Keytruda, sending Moderna shares up roughly 170% in a single day. The results came from a trial involving more than 1,000 participants, following earlier confirmation of efficacy in a roughly 150-participant Phase 2 trial.
The mRNA technology works by identifying specific proteins in a patient's own cancer cells and synthesizing a personalized vaccine trained on them, teaching the body's immune cells to attack those cancer cells. First popularized through COVID-19 vaccines, this is regarded as the first case proving the technology's efficacy in oncology, with trials for cancer types beyond melanoma reportedly also underway.
Domestically, Alteogen—a partner of Keytruda—was highlighted for its involvement in the combination trial, surging more than 10%, and attention turned to whether this would positively affect the KOSDAQ index given Alteogen's status as the largest company by market cap on KOSDAQ. Merck also surged about 12% to a record high, aided by a contract structure under which it shares a substantial portion of the revenue upon commercialization.